We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

VRX.TO
Valeant Pharmaceuticals International, Inc.
Toronto
People also watch : CXR.TO MG.TO DOL.TO ATD-B.TO POT.TO
30.03 -2.00 (-6.24%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 32.03
Open 31.55
Bid 30.01 x
Ask 30.03 x
52wk Range 24.32 - 347.84
Day's Range 29.90 - 31.82
Volume 1,028,261
Avg Vol (3m) 1,302,239
As of 3:59 PM EDT. Market closed.
  • Reuters 1 hour ago

    CANADA STOCKS-TSX at highest close in year, 4th weekly gain; telecoms shine

    Canada's main stock index hit its highest close in a year on Friday, notching a fourth straight weekly gain as yield-producing telecom and utility stocks found favor, offsetting a plunge in shares of Valeant ...

  • American City Business Journals 4 hours ago

    ‘Deficiencies’ at Bausch + Lomb manufacturing plant in Tampa put glaucoma drug on hold

    Concerns about a Bausch + Lomb manufacturing facility in Tampa have put a hold on a drug to treat certain types of eye diseases. The U.S. Food & Drug Administration said it won’t approve, at least for now, a drug being developed to treat open angle glaucoma or ocular hypertension. “The concerns raised by the FDA pertain to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb’s manufacturing facility in Tampa, Florida where some deficiencies were identified by the FDA,” said a statement from Valeant Pharmaceuticals International Inc. (VRX), Bausch & Lomb’s parent company.

  • TheStreet.com 6 hours ago

    Valeant Hits Another Bump

    The beleaguered drugmaker says the FDA raised red flags at a Tampa-based manufacturing plant.

  • TheStreet.com 6 hours ago

    Valeant Slides as FDA Report Hampers Drug Application

    Valeant's pipeline drug has so far failed to pass FDA muster following a manufacturing plant inspection.

  • Valeant just got blindsided
    Business Insider 6 hours ago

    Valeant just got blindsided

    The last week or so was supposed to be one of tiny tidbits of happy news for Valeant...

  • MarketWatch 7 hours ago

    Valeant’s latest woe isn’t even financial

    The FDA declined to approve the drug company’s glaucoma eye drop treatment because of manufacturing facility problems.

  • Barrons.com 7 hours ago

    Valeant Pharmaceuticals: It Had to End Some Time

    Valeant Pharmaceuticals International (VRX) had been on quite a run this month but its shares are tumbling this morning after the beleaguered specialty pharmaceutical company didn't receive an FDA approval for its glaucoma treatment. Rodman & Renshaw's Raghuram Selvaraju still expects the drug to be approved: Early this morning, Valeant disclosed that it had received a Complete Response Letter (CRL) from the FDA on its New Drug Application (NDA) for Vesneo® (latanoprostene bunod 0.024% ophthalmic solution), an intra-ocular pressure (IOP)-lowering single-agent eye drop product for treatment of open angle glaucoma or ocular hypertension. In our view, while this is clearly a disappointing setback in a month that to date had proved to be one of positive surprises for the company, Vesneo® should still ultimately receive regulatory approval, as no safety or efficacy issues with the drug were cited in the CRL.

  • The Wall Street Journal 8 hours ago

    Valeant: Not All Delays Are Created Equal

    Valeant Pharmaceuticals International shareholders just can’t catch a break.

  • Reuters 8 hours ago

    CANADA STOCKS-TSX flat as Valeant, miners weigh; eyes fourth weekly gain

    Canada's main stock index slipped on Friday but was on track for its fourth straight weekly gain as losses for materials stocks and Valeant Pharmaceuticals International Inc were offset by rising telecom, ...

  • TheStreet.com 8 hours ago

    Valeant (VRX) Stock Down on Concerns About Glaucoma Treatment

    Valeant (VRX) stock is lower this morning after the FDA decided against approving its glaucoma treatment.